Antigen epitope for exciting protective immunity against tubercle bacillus of human body and uses thereof

Abstract

The invention relates to the field of molecular immunology. In recent years, tuberculosis revives in the global range. The emergence of drug-resistant strain always invalidates antibiotic therapy and the normally used tuberculosis vaccine-BCG vaccine also has limitations. The invention aims at screening the molecular simulation peptide of epitope which can activate the protective immune response of human anti-mycobacterium tuberculosis, studying the protective immune response mechanism of the tuberculosis and further developing a novel concatenated poly epitope tuberculosis vaccine. The invention provides the molecular simulation peptide of the epitope which can activate the protective immune response of human anti-mycobacterium tuberculosis; the amino acid sequence of the peptide is shown as SEQ ID NO:14. The invention further provides a screening method and the function of the peptide. Therefore, the molecular simulation peptide of the invention can more effectively prevent and control the generation and the development of the tuberculosis.

Description

This application is a divisional application of the patent application filed on June 6, 2006 with the application number 200610027311.2 and the title of the invention is "antigen epitope for stimulating human body's protective immune response against Mycobacterium tuberculosis and its use". Technical field: The invention relates to the field of molecular immunology, in particular to a molecular mimetic peptide capable of stimulating a human body's protective immune response against Mycobacterium tuberculosis and its screening method and application. Background technique: In recent years, tuberculosis (Tuberculosis, TB) has resurged worldwide. According to the statistics of the World Health Organization, about 1 / 3 of the world's population and about 2 billion people are infected with Mycobacterium tuberculosis (Mtb). There are about 9 million new cases every year, and the annual death toll is as high as 3 million. The World Health Organization has proposed a "global tubercu...

AI Technical Summary

Problems solved by technology

However, multiple antibiotics need to be used in combination for at least 6 months, and due to the widespread emergence of Mtb drug-resistant strains, antibiotic treatment is often ineffective

The tuberculosis vaccine commonly used today, Bacillus Calmette-Guerin (BCG), has significant limitations: (1) Its effect on adult tuberculosis is not satisfactory; (2) It can cause severe disease and even death in immunocompromised individuals (3) It can cause positive skin test, making it lose its diagnostic significance in Mycobacterium tuberculosis infection

While vaccine research has focused on immunodominant epitopes, studies of minor determinants may focus the immune response on epitopes that cannot escape immune recognition

It has been reported that immunization of mice with a minor determinant of ESAT-6 can induce a significant protective immune response against TB, while some immunodominant epitopes cannot produce such a protective response

Images